For example, a case report demonstrated that a GIST patient with low KIT expression had response to imatinib treatment [190], and 6 patients without typical target mutations of imatinib were still sensitive to imatinib therapy [175]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.